Antonella Folgori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8303378/publications.pdf

Version: 2024-02-01

687363 1058476 1,750 14 13 14 citations h-index g-index papers 14 14 14 2120 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. Science Translational Medicine, 2022, 14, eabj1996.	12.4	18
2	Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19. Molecular Therapy, 2021, 29, 2412-2423.	8.2	41
3	Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19. Npj Vaccines, 2021, 6, 131.	6.0	18
4	MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans. Science Translational Medicine, 2020, 12, .	12.4	20
5	A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection. Frontiers in Immunology, 2018, 9, 3175.	4.8	27
6	Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain. PLoS ONE, 2014, 9, e100538.	2.5	33
7	Fusion of HCV Nonstructural Antigen to MHC Class Il–associated Invariant Chain Enhances T-cell Responses Induced by Vectored Vaccines in Nonhuman Primates. Molecular Therapy, 2014, 22, 1039-1047.	8.2	29
8	A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Science Translational Medicine, 2014, 6, 261ra153.	12.4	297
9	Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization. Journal of Immunology, 2013, 190, 2720-2735.	0.8	99
10	Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species. Science Translational Medicine, 2012, 4, 115ra2.	12.4	257
11	Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man. Science Translational Medicine, 2012, 4, 115ra1.	12.4	356
12	Prime-boost vectored malaria vaccines: Progress and prospects. Hum Vaccin, 2010, 6, 78-83.	2.4	184
13	A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nature Medicine, 2006, 12, 190-197.	30.7	289
14	A Novel Adenovirus Type 6 (Ad6)-Based Hepatitis C Virus Vector That Overcomes Preexisting Anti-Ad5 Immunity and Induces Potent and Broad Cellular Immune Responses in Rhesus Macaques. Journal of Virology, 2006, 80, 1688-1699.	3.4	82